A platform built around one question
Which expression system will give this molecule the highest, most stable, most manufacturable yield? Titre is rarely the only constraint — clone stability, correct chain pairing, glycosylation and developability all matter. We choose the host and engineering strategy from the molecule and its target profile, never the other way around.
The host follows the molecule
We are host-agnostic by design. A glycosylated monoclonal antibody calls for a different system than a non-glycosylated peptide or an antibody fragment, so we maintain genuine breadth across mammalian, microbial and yeast expression alongside the engineering needed for complex formats.
Constructs and expression strategies are screened in parallel, ranked against titre, product quality and developability criteria, and confirmed with analytical and stability data before we commit a programme to a single clone and process.
The expression toolbox
A complementary set of mammalian, microbial and engineering technologies — applied individually or in combination to hit titre, quality and timeline.
CHO mammalian expression
A high-titre stable CHO platform with metabolic selection for monoclonal antibodies and complex proteins — our workhorse from cell line through to GMP.
Transposon-based stable pools
Rapid, high-expressing stable pools that deliver representative material in weeks, not months — ideal for early supply while the clonal line is finalised.
Transient expression
HEK and CHO transient production for fast gram-scale material — supporting research reagents, candidate screening and tox studies in days to weeks.
Microbial expression
E. coli and Pichia / yeast systems for non-glycosylated proteins, peptides and antibody fragments where speed, cost and simplicity matter.
Multispecific chain-pairing
Engineering for correct heavy- and light-chain pairing in bispecific and multispecific formats, maximising the fraction of correctly assembled product.
Glycoengineering & effector tuning
Fucose-reduced and glyco-optimised lines for enhanced effector function (ADCC), plus developability and immunogenicity screening to de-risk the candidate.
How we engineer for yield
Match the host to the molecule
Format, glycosylation needs, target profile and timeline are mapped first. The molecule dictates the expression system and engineering strategy — not house preference.
Manufacturability by design
Clone stability, product quality and developability are assessed alongside titre from the first screen, so a high-expressing pool also survives scale-up and the journey to GMP.
A documented, regulatory-ready lineage
Clonal derivation, monoclonality assurance and full cell-line history are captured as we go, so the line you take forward carries a clean CMC and regulatory narrative.
Programmes we're built for
Antibodies & complex biologics
Monoclonal antibodies, bispecifics, Fc-fusion proteins and complex recombinant proteins that need high, stable titres and well-controlled product quality to support a clinical programme.
Difficult-to-express targets
Molecules that have stalled on low titre, instability or incorrect chain pairing — where targeted host selection and engineering can recover yield and quality.
See how the platform maps to your stage
From a feasibility pool to a documented clonal line and GMP material, our services flex to where your programme is today.